Human cytomegalovirus (HCMV) reactivation poses a serious challenge in patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) for an underlying hematologic malignancy. 1 Predictors of HCMVtreatment response in patients receiving prophylactic and/ or pre-emptive anti-HCMV therapy during high-risk post transplant periods remain uncertain. 2 Shell-vial culture, pp65 antigenemia assay, qualitative peripheral blood leukocyte (PBL) PCR, qualitative serum PCR and semiquantitative plasma or PBL HCMV PCR are currently employed in hybrid protocols to determine viral reactivation and response to therapy. 3, 4 In this prospective study (January 1999-December 2000), serial qualitative PCR and quantitative PCR were performed weekly (À10 to þ 100 days) in HCMV-seropositive recipients of allogeneic HSCT at Palmetto-Richland Memorial Hospital, Columbia, South Carolina. 5 HCMV quantitative-PCR (CMV Ultraquant assay, Specialty Laboratories, Santa Monica, CA) used 5 0 -3 0 exonuclease activity of Taq DNA polymerase Gold (PE Applied Biosystems, Foster City, CA, USA) for direct detection of the amplified PCR product (CMV DNA polymerase gene) by the release of a fluorescent reporter. The detection range for this test was 200 to 1 million copies/ml. By quantitative PCR, HCMV was detected as early as 7 days post HSCT, whereas qualitative PCR detected viral presence in peripheral blood lymphocytes after the third week of transplantation (24-38 days post HSCT). Quantitative PCR was positive in the setting of low-level viral DNA presence (234 copies/ml), whereas, for qualitative PCR to become positive, 42000 HCMV copies/ml were needed. In three patients with early post transplant viral detection on days 7, 12, and 17, levels of peripheral blood lymphocyte viral burden were lower (234, 311, and 258 copies/ml, respectively) compared to patients in whom HCMV was detected late (days 26 (1270 copies/ml); day 31 (1312 copies/ml), and day 35 (9307 copies/ml)).
The median interval between transplantation and ganciclovir therapy was 26-51 days (Table 1) . Three patients had a marked decline (2-5 log 10 ) in viral DNA after 37-39 days following induction dose ganciclovir therapy (5 mg/kg 12 h). In the other three, a progressive rise (X1.0 log 10 ) in HCMV DNA occurred 13-32 days after institution of ganciclovir; all the three patients had marked viral suppression (2-4 log 10 HCMV viral load decline in 6-32 days) after treatment was change to foscarnet (60 mg/kg, 8 h), although two of three patients (67%) that failed initial ganciclovir therapy died due to progressive viral interstitial pneumonitis (Table 1) .
In these high-risk stem-cell transplant recipients, realtime quantitative HCMV PCR provided the following: (1) early detection (B2 weeks post HSCT) of HCMV in patients' peripheral blood lymphocyte, during a period often associated with low-level viremia. (2) Paradoxical rise in HCMV DNA in patients receiving ganciclovir therapy appears as an early indicator of suboptimum antiviral treatment response. This suboptimum response to ganciclovir may be an indication of non-(ganciclovir)susceptible virus; however, to support this hypothesis, drug-resistance analysis will be needed; alternatively, profound defect in hosts' immune function, especially in patients receiving cytoablative therapy for acute GvHD, may lead to immunologic escape and high-level HCMV viremia, although only one of three patients in this group had severe GvHD, and non-received ATG, or dacluzimab s (anti-IL-2 receptor antibodies) ( Table 1) . (3) Interestingly, despite a favorable antiviral response to foscarnet plus anti-HCMV-enriched immunoglobulin therapy (Table 1) , viral pneumonitis, once established, was associated with high mortality. This observation was in concert with other reports, indicating that high viral load at the onset of infection or rising viremia in stem-cell transplant recipients, while on anti-HCMV therapy has a higher risk of imminent disease and unfavorable outcome. 6, 7 In this preliminary Table 1 Serial quantitative HCMV PCR (viral load copies/ml) in patents with allogeneic hematopoietic stem cell transplantation (HSCT)
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